Livtencity Side Effects

Generic name: maribavir

Medically reviewed by Drugs.com. Last updated on Dec 27, 2024.

Note: This document provides detailed information about Livtencity Side Effects associated with maribavir. Some dosage forms listed on this page may not apply specifically to the brand name Livtencity.

Applies to maribavir: oral tablet.

Precautions

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood tests may be needed to check for unwanted effects.

Do not use this medicine together with ganciclovir (Cytocvene®) or valganciclovir (Valcyte®).

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal (St. John's wort) or vitamin supplements.

Common side effects of Livtencity

Some side effects of maribavir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Serious side effects of Livtencity

Along with its needed effects, maribavir (the active ingredient contained in Livtencity) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

For healthcare professionals

Applies to maribavir: oral tablet.

General adverse events

The most commonly reported adverse reactions in patients treated with this drug were taste disturbance, nausea, diarrhea, vomiting, and fatigue. The most commonly reported serious adverse reactions were diarrhea, nausea, decreased weight, fatigue, immunosuppressant drug level increased, and vomiting. More patients in the investigator-assigned treatment group (32%) discontinued therapy due to a side effect compared to those in the group using this drug (13%); the most common side effects leading to discontinuation of this drug were dysgeusia, diarrhea, nausea, and recurrence of underlying disease.^[Ref]

Cardiovascular

• Common (1% to 10%): Hypertension

Gastrointestinal

• Very common (10% or more): Nausea (up to 21%), diarrhea (up to 19%), vomiting (up to 14%)
• Common (1% to 10%): Upper abdominal pain

Hematologic

• Very common (10% or more): Decreased hemoglobin (up to 32%), decreased platelets (up to 18%)
• Common (1% to 10%): Decreased neutrophils, neutropenia, leukopenia

Decreased hemoglobin (8 to less than 9.5 g/dL: 32%; 6.5 to less than 8 g/dL: 15%; less than 6.5 g/dL: 1%), platelets (50,000 to less than 100,000 cells/mcL: 18%; 25,000 to less than 50,000 cells/mcL: 12%; less than 25,000 cells/mcL: 5%), and neutrophils (750 to less than 1000 cells/mcL: 4%; 500 to less than 750 cells/mcL: 3%; less than 500 cells/mcL: 2%) have been reported.

Metabolic

• Common (1% to 10%): Hypomagnesemia, hypokalemia, decreased appetite

Nervous system

• Very common (10% or more): Taste disturbance (includes ageusia, dysgeusia, hypogeusia, taste disorder; up to 46%)
• Common (1% to 10%): Headache

Taste disturbance was reported in 46% of patients using this drug; this resolved in 37% of patients during therapy (median duration: 43 days; range: 7 to 59 days) and rarely resulted in discontinuation of this drug. For patients with ongoing taste disturbances after stopping this drug, resolution occurred in 89%; the median duration of symptoms off therapy was 6 days (range: 2 to 85 days).

Other

• Very common (10% or more): Fatigue (up to 12%)
• Common (1% to 10%): Pyrexia, peripheral edema, immunosuppressant drug level increased (includes immunosuppressant drug level increased, drug level increased), decreased weight
• Frequency not reported: CMV infection/disease, recurrence of underlying disease

Renal

• Very common (10% or more): Increased creatinine (up to 33%)
• Common (1% to 10%): Acute kidney injury

Increased creatinine greater than 1.5 to 2.5 mg/dL was reported in 33% of patients; increased creatinine greater than 2.5 mg/dL was reported in 7% of patients.

See also:

Further information

Livtencity side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer